Nautilus Biotechnology, Inc. NAUT
Biotechnology: Laboratory Analytical Instruments · IPO 2020 · data as of November 13, 2026
Nautilus Biotechnology, Inc. (NAUT) is a industrial company listed in the US with a market value of about $296M. In the twelve months to September 30, 2026 it had revenue of $36000 and net income of -$59M, a net margin of -162730.6%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
About Nautilus Biotechnology
Nautilus Biotechnology is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2020. It was profitable in 0 of the last 6 years in our data.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $36000 | — | — | — | — | — | — |
| Net income | -$59M | -$59M | -$71M | -$64M | -$58M | -$50M | -$16M |
| Free cash flow | -$55M | -$52M | -$61M | -$54M | -$48M | -$42M | -$15M |
| EPS (diluted) | $-0.46 | $-0.47 | $-0.56 | $-0.51 | $-0.46 | $-0.60 | $-0.54 |
| Net margin | -162730.6% | — | — | — | — | — | — |
| ROIC | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $4.00, 72% above the current price; targets range from $4.00 to $4.00; the consensus rating is “none”; expected EPS is $-0.48 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Nautilus Biotechnology pay a dividend?
Not currently.
Is Nautilus Biotechnology a good stock to buy?
We do not give buy or sell advice. Nautilus Biotechnology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.